NCT03196232View on ClinicalTrials.gov

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

May 29, 2018

Study Completion Date

May 29, 2018

Conditions
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaRecurrent Esophageal CarcinomaRecurrent Gastric CarcinomaStage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Unresectable Esophageal Carcinoma
Interventions
DRUG

Epacadostat

Given PO

DRUG

Pembrolizumab

Given IV

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

George Albert Fisher

OTHER

NCT03196232 - Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | Biotech Hunter | Biotech Hunter